Flamel announces Hepatitis C trial results

Sep. 26, 2005 – Flamel Technologies S.A. (NASDAQ:FLML) announced positive preliminary Phase I and II data from a trial demonstrating the safety, tolerability, and long-acting activity of IFN-alpha-XL in patients with chronic hepatitis C virus infection.

The company said that data show that the drug had positive effects on viral load and interferon activity biomarkers. IFN-alpha-XL utilizes Flamel’s proprietary Medusa nanoparticle technology to provide a long-acting formulation of interferon alpha that may have enhanced efficacy and reduced toxicity.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.